MOA Life Plus
모아라이프플러스 · 142760
Industrials Commercial Services · KOSDAQ
Market cap US$21.6M (₩29.8B)
Overview
MOA Life Plus develops biopharmaceutical drug candidates and makes health supplements and skincare products built around a natural polymer ingredient called poly-gamma-glutamic acid (γ-PGA).
Its consumer products reach both individual shoppers and business customers, while a separate division distributes prescription drugs, over-the-counter medicines, and medical supplies through specialist wholesalers. Listed on KOSDAQ, Korea's tech and small-cap board, the company runs three distinct lines, drug development, consumer goods, and pharmaceutical distribution, under one roof.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$13.2M
- FY2024US$11.3M
- FY2025US$8.1M
Operating profit
- FY2023−US$3.7M
- FY2024−US$4M
- FY2025−US$4.7M
Net income
- FY2023US$5.9M
- FY2024−US$5.1M
- FY2025−US$9.5M
Key ratios (FY2025)
Why it matters
The company holds its γ-PGA ingredient approved as a functional raw material by Korea's Ministry of Food and Drug Safety, and separately cleared as a New Dietary Ingredient by the US FDA, enabling overseas market entry.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?